Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers

This study has been completed.
Sponsor:
Collaborator:
Assistance Publique - Hôpitaux de Paris
Information provided by (Responsible Party):
University Hospital, Angers
ClinicalTrials.gov Identifier:
NCT00188019
First received: September 12, 2005
Last updated: July 22, 2015
Last verified: July 2015
  Purpose

Hereditary paraganglioma -due to SDH (SDHD, SDHB, SDHC) germline mutations- causes paragangliomas and pheochromocytomas. Presymptomatic genetic testing should be offered to all first-degree relatives if an SDH mutation is detected in an index case with paraganglioma or pheochromocytoma. The main objective of our national clinical research project is to test different screening methods to detect presymptomatic tumors in order to establish guidelines for the work-up and the follow-up of SDH mutation carriers.


Condition Intervention
Paraganglioma
Pheochromocytoma
Procedure: diagnosis methods

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Evaluation Des méthodes de dépistage du Paragangliome héréditaire Chez Les Sujets prédisposés génétiquement

Resource links provided by NLM:


Further study details as provided by University Hospital, Angers:

Enrollment: 248
Study Start Date: November 2005
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: identification of an SDH (SDHD, SDHD, SDHC) germline mutation

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00188019

Locations
France
Européen Georges Pompidou Hospital
Paris, France, 75015
Sponsors and Collaborators
University Hospital, Angers
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Vincent Rohmer, MD University Angers Hospital
Principal Investigator: Anne-Paule Gimenez-Roqueplo, MD, PhD Paris-Descartes University, Européen Georges Pompidou Hospital, Assistance Publique des Hôpitaux de Paris
  More Information

No publications provided

Responsible Party: University Hospital, Angers
ClinicalTrials.gov Identifier: NCT00188019     History of Changes
Other Study ID Numbers: PHRC 04-01
Study First Received: September 12, 2005
Last Updated: July 22, 2015
Health Authority: France: Ministry of Health

Additional relevant MeSH terms:
Paraganglioma
Pheochromocytoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors

ClinicalTrials.gov processed this record on August 31, 2015